Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 57
- Registration Number
- NCT01359969
- Locations
- 🇮🇱
Sheba Medical Center, Tel Hashomer, Israel
🇷🇴Mures County Clinical Hospital, Targu Mures, Romania
🇮🇱Bnei Zion Hospital, Haifa, Israel
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2015-08-07
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 75
- Registration Number
- NCT01188564
- Locations
- 🇺🇸
Family Allergy and Asthma Center, Atlanta, Georgia, United States
🇺🇸Allergy, Asthma & Immunology, Assoc, Ltd., Scottsdale, Arizona, United States
🇺🇸Allergy and Asthma Institute of the Valley, Granada Hills, California, United States
Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation
- Conditions
- Interventions
- First Posted Date
- 2009-12-18
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Pharming Technologies B.V.
- Registration Number
- NCT01035593
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration
- Conditions
- Interventions
- First Posted Date
- 2009-02-26
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 25
- Registration Number
- NCT00851409
- Locations
- 🇷🇴
Emergency County Hospital, Internal Medicin Clinica, Allergology-Immunology Department, Târgu-Mureş, Romania
🇳🇱For information on sites, please contact Pharming Technologies, Leiden, Netherlands
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2013-02-22
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 14
- Registration Number
- NCT00262288
- Locations
- 🇳🇱
For information on sites in Europe, please contact Pharming Technologies., Leiden, Netherlands
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
- Conditions
- Interventions
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2012-10-02
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 75
- Registration Number
- NCT00262301
- Locations
- 🇷🇴
Emergency County Hospital, Internal Medicin Clinica, Allergology-Immunology Department, Tirgu Mures, Romania
🇳🇱For information on sites, please contact Pharming Medical Affairs Deparment, Leiden, Netherlands
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
- First Posted Date
- 2005-12-02
- Last Posted Date
- 2013-04-25
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 14
- Registration Number
- NCT00261053
- Locations
- 🇳🇱
For information contact Sonja Visscher, Leiden, Netherlands
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
- Conditions
- Interventions
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2013-02-22
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 77
- Registration Number
- NCT00225147
- Locations
- 🇳🇱
For information on sites please contact Pharming Medical Affairs Department, Leiden, Netherlands